PubMed

Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.

Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R.

J R Soc Med. 2006 Mar;99(3):132-40. Review.PMID: 16508052 [PubMed - indexed for MEDLINE]Related articlesFree article

Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.

Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E; Cross Trial Safety Assessment Group.

Circulation. 2008 Apr 22;117(16):2104-13. Epub 2008 Mar 31.PMID: 18378608 [PubMed - indexed for MEDLINE]Related articlesFree article

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.

Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.

Health Technol Assess. 2008 Apr;12(11):1-278, iii. Review.PMID: 18405470 [PubMed - indexed for MEDLINE]Related articlesFree article

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

McGettigan P, Henry D.

JAMA. 2006 Oct 4;296(13):1633-44. Epub 2006 Sep 12. Review.PMID: 16968831 [PubMed - indexed for MEDLINE]Related articlesFree article

Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.

White WB, Faich G, Borer JS, Makuch RW.

Am J Cardiol. 2003 Aug 15;92(4):411-8.PMID: 12914871 [PubMed - indexed for MEDLINE]Related articles

Risk of cardiovascular events associated with selective COX-2 inhibitors.

Mukherjee D, Nissen SE, Topol EJ.

JAMA. 2001 Aug 22-29;286(8):954-9. Review.PMID: 11509060 [PubMed - indexed for MEDLINE]Related articles

Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis.

Aldington S, Shirtcliffe P, Weatherall M, Beasley R.

N Z Med J. 2005 Nov 25;118(1226):U1755. Review.PMID: 16311613 [PubMed - indexed for MEDLINE]Related articles

Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.

Huang WF, Hsiao FY, Tsai YW, Wen YW, Shih YT.

Drug Saf. 2006;29(3):261-72.PMID: 16524325 [PubMed - indexed for MEDLINE]Related articles

Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.

White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX, Weiner E, Verburg KM.

Am J Cardiol. 2007 Jan 1;99(1):91-8. Epub 2006 Nov 10.PMID: 17196469 [PubMed - indexed for MEDLINE]Related articles

Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.

Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, Worchel J.

Drug Saf. 2006;29(7):621-32.PMID: 16808554 [PubMed - indexed for MEDLINE]Related articles

Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.

Huang WF, Hsiao FY, Wen YW, Tsai YW.

Clin Ther. 2006 Nov;28(11):1827-36.PMID: 17213003 [PubMed - indexed for MEDLINE]Related articles

Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention.

Feng GS, Ma JL, Wong BC, Zhang L, Liu WD, Pan KF, Shen L, Zhang XD, Li J, Xia HH, Li JY, Lam SK, You WC.

World J Gastroenterol. 2008 Jul 28;14(28):4535-9.PMID: 18680235 [PubMed - indexed for MEDLINE]Related articlesFree article

Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials.

Zhang J, Ding EL, Song Y.

JAMA. 2006 Oct 4;296(13):1619-32. Epub 2006 Sep 12. Review.PMID: 16968832 [PubMed - indexed for MEDLINE]Related articlesFree article

[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?]

Valat JP, Deray G, Héloire F.

Presse Med. 2006 Sep;35(9 Spec No 1):1S25-34. Review. French. PMID: 17078592 [PubMed - indexed for MEDLINE]Related articles

A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.

Kasliwal R, Layton D, Harris S, Wilton L, Shakir SA.

Drug Saf. 2005;28(9):803-16.PMID: 16119973 [PubMed - indexed for MEDLINE]Related articles

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.

Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators.

N Engl J Med. 2005 Mar 17;352(11):1071-80. Epub 2005 Feb 15.PMID: 15713944 [PubMed - indexed for MEDLINE]Related articlesFree article

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports.

Moore RA, Derry S, Makinson GT, McQuay HJ.

Arthritis Res Ther. 2005;7(3):R644-65. Epub 2005 Mar 24. Review. Erratum in: Arthritis Res Ther. 2006;8(1):401. PMID: 15899051 [PubMed - indexed for MEDLINE]Related articlesFree article

Systematic review and meta-analysis of the risk of major cardiovascular events with etoricoxib therapy.

Aldington S, Shirtcliffe P, Weatherall M, Beasley R.

N Z Med J. 2005 Oct 7;118(1223):U1684. Review.PMID: 16224508 [PubMed - indexed for MEDLINE]Related articles

Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.

White WB, Faich G, Whelton A, Maurath C, Ridge NJ, Verburg KM, Geis GS, Lefkowith JB.

Am J Cardiol. 2002 Feb 15;89(4):425-30.PMID: 11835924 [PubMed - indexed for MEDLINE]Related articles

Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.

Chen LC, Ashcroft DM.

Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):762-72.PMID: 17457957 [PubMed - indexed for MEDLINE]Related articles